Abstract
Introduction:
Vaccination is an essential intervention to curb the coronavirus disease 2019 (COVID-19) pandemic. This review aimed to estimate the pooled proportion of COVID-19 vaccine acceptance worldwide.
Methods:
A systematic search of the MEDLINE (PubMed) database using “COVID-19,” “vaccine” and “acceptance” to obtain original research articles published between 2020 and July 2021. Only studies with full text and that were published in English were included. The Joanna Briggs Institute meta-analysis was used to assess the data quality. The meta-analysis was performed using generic inverse variance with a random-effects model using the Review Manager software.
Results:
A total of 172 studies across 50 countries worldwide were included. Subgroup analyses were performed with regard to vaccine acceptance, regions, population, gender, vaccine effectiveness, and survey time. The pooled proportion of COVID-19 vaccine acceptance was 61% (95% CI: 59, 64). It was higher in Southeast Asia, among healthcare workers, in males, for vaccines with 95% effectiveness, and during the first survey.
Conclusion:
COVID-19 vaccine acceptance needs to be increased to achieve herd immunity to protect the population from the disease. It is crucial to enhance public awareness of COVID-19 vaccination and improve access to vaccines.
Systematic Review Registration:
PROSPERO 2021, identifier CRD42021268645.
Introduction
The coronavirus disease 2019 (COVID-19) pandemic is a global health topic of concern. As of August 2021, nearly 216 million COVID-19 cases have been reported globally, with the cumulative number of deaths being just under 4.5 million (1). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, has changed over time. Change in the virus's properties may affect disease transmissibility, severity, and vaccine efficacy. The World Health Organization (WHO) has identified four SARS-CoV-2 variants of concern, namely alpha, beta, gamma, and delta, and five variants of interest, namely eta, iota, kappa, lambda, and mu (2).
In December 2020, the WHO approved the first vaccine, BNT162b2/COMIRNATY, which contains modified nucleoside mRNA that confers protection against COVID-19 (3). The United States Food and Drug Administration has granted emergency use authorization to use the COVID-19 vaccines and full approval for Pfizer vaccine to control the pandemic. The WHO has also recommended several vaccines for COVID-19, including COVISHIELD™, Janssen, Vaxzervria, Moderna, BIBP, CoronaVac, and AstraZeneca (3). The vaccines have the potential to create herd immunity without causing illness and complications (4). Herd immunity requires sufficient coverage and a large proportion of the population to be vaccinated.
However, the effectiveness of vaccination depends on the population's willingness to accept the vaccines. This urgent use of newly developed vaccines evokes a sense of vigilance in the general population. Many factors influence the population's acceptance of the vaccination, including risk perception of the disease, perception of vaccine safety and efficacy, public vaccination attitudes, past vaccination history, doctor's recommendations, costs, convenience, and sociodemographic characteristics (5).
Many studies have explored public perceptions of the COVID-19 vaccination program. The acceptance of COVID-19 vaccines varies among countries globally (6). Some studies showed a high level of vaccination acceptance (5, 7–12), while others reported an average level of acceptance (7, 8). An analysis of social media users indicated that of all participants involved, 36.4% in New York, 51.3% in London, 67.3% in São Paulo, 69.8% in Mumbai, and 76.8% in Beijing were willing to accept COVID-19 vaccines (9). An online survey in Arab countries reported that 83% of the study participants were hesitant to accept the vaccines because of their side effects, distrust in health care policies, the expedited production of vaccines, published studies, and vaccine-producing companies (10).
Determining the pooled estimated proportion of COVID-19 vaccination acceptance provides guidance to health authorities to prepare for an effective vaccination program. A successful and effective vaccination program can provide sufficient vaccination coverage in a population to achieve herd immunity and subsequently control the COVID-19 pandemic. Thus, this review aims to assess the estimated proportion of acceptance of the COVID-19 vaccines.
Methods
Study Design
A systematic review and meta-analysis of studies were conducted to assess the proportion of COVID-19 vaccination acceptance. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (11) were followed to review articles of the studies. Ethics review and approval are not required for analyses of published data. This review was registered in PROSPERO 2021 (CRD42021268645).
Eligibility Criteria
The criteria for inclusion include studies that report the proportion of COVID-19 vaccination acceptance. The acceptance of the vaccines included studies before or after the availability of COVID-19 vaccines. All types of COVID-19 vaccines were included in this review. Studies with cross-sectional, case-control, and cohort designs published in English from 2020 to 19 July 2021 were included. Case series/reports, conference papers, proceedings, articles available only in abstract form, editorial reviews, letters of communications, commentaries, systematic reviews, and qualitative studies were excluded. Articles in languages other than English were also be excluded.
Information Sources
A systematic search was performed in the MEDLINE (PubMed) database for articles between 1 January 2020 and 19 July 2021.
Search Strategy
The search was done using the generic free-text search terms “COVID-19” AND “vaccine” AND “acceptance.” All studies published from 2020 to 19 July 2021 were retrieved to assess their eligibility for inclusion in this study. The search was restricted to full-text only and English language articles. To find additional potentially eligible studies, reference lists of included citations were cross-checked.
Selection Process
All records identified by our search strategy were exported to EndNote software. Duplicate articles were removed from the list. One independent reviewer screened the titles and abstracts of the identified articles. The full texts of eligible studies were obtained and read thoroughly to assess their suitability. The second reviewer validated the records. A third reviewer was consulted in the event of a conflict between the two reviewers. The search method was presented in the PRISMA flow chart showing the included studies and excluded with reasons for exclusion.
Data Collection Process and Data Items
The data was extracted into Microsoft Excel (Microsoft Office Professional Plus 2016). The data included the first author, year of publication, study location, study design, setting, study population, sample size, proportion, and data to calculate effect estimates.
Study Risk of Bias Assessment
Assessment of critical appraisal for data quality was assessed using the Joanna Briggs Institute (J.B.I.). Meta-Analysis for cross-sectional, case-control, and cohort studies (12). Two authors performed bias assessments independently.
Effect Measures
The proportion of vaccines acceptance was reported in pooled estimate proportion with a 95% confidence interval. Terminology of vaccines acceptance refers to the willingness to be vaccinated, vaccines acceptability, desirability, demand, and positive attitudes toward the given vaccines.
Synthesis Methods
The analysis was performed with Review Manager (RevMan) software (13). A generic inverse variance with a random-effects model was applied to pool the proportion of the studie's data. The heterogeneity was assessed by I2 statistic and used the guide as outlined: 0% to 40% might not be important; 30 to 60% may represent moderate heterogeneity; 50 to 90% may represent substantial heterogeneity; and 75 to 100% would be considerable heterogeneity (14). Subgroup analysis was performed based on WHO classification of world regions (African/American/Eastern Mediterranean/European/ South-East Asian/ Western Pacific), type of population (college students/ general adult/ healthcare/ high risk/ parents and caregivers), gender (male/ female), vaccines effectiveness (at 90% effective/ at 95% effective) and survey time (first survey/ second survey). The high-risk population represented people most at risk of exposure, such as teachers and school students, detained people, patients, and pregnant and breastfeeding women.
Reporting Bias Assessment
The risk of bias was assessed by nine criteria (15): (1) appropriateness of sample frame (2) appropriateness of study participants sampled (3) adequate of sample size (4) description of study subjects and the setting (5) sample size justification, power description, or variance and effect estimates (6) valid methods for the identification of the condition (7) a standard and reliable condition measured (8) appropriateness of statistical analysis (9) adequate of response rate.
The criteria of the risk assessment were represented by “yes,” “no,” “unclear” or “not available.” The score for yes was one (1) and zero (0) for the rest. The risk of bias was considered low when the total score was more than 70%, moderate when 50–69%, and high when up to 0–49% (16).
Results
Study Selection
The primary search through the database had identified 678 studies. One duplicated study was removed, and 677 studies were screened for the titles and the abstracts. A total of 466 studies were excluded, and 211 full-text articles were assessed for eligibility. Thirty-nine studies were excluded for systematic review articles, out of interest outcomes, not research articles, and qualitative study articles. As a result, a total of 172 studies that met the inclusion and exclusion criteria were included for the review and meta-analysis (Figure 1).
Figure 1
Study Characteristics
The articles of included studies were published in 2020 (n = 18) and in 2021 (n = 154). The studies involved 814,691 participants from 50 countries across six regions in the world represented as African region (n = 14) (17–30), American region (n = 34) (7, 31–63), Eastern Mediterranean region (n = 33) (8, 64–95), European region (n = 46) (96–141), South-East Asian region (n = 8) (5, 142–148) and Western Pacific region (n = 31) (149–179). There were two global studies (180, 181), one study combined countries in the European region and Western Pacific region (182), one study involved countries in the American region and Western Pacific region (183), one study involved the African region and Middle East countries (184) and one study involved countries in the African region, American region and South-East Asian region (185).
Most of the studies were designed as cross-sectional studies (n = 140), cohort studies (n = 4), descriptive studies (n = 23), longitudinal studies (n = 4) and combination of cross-sectional and longitudinal study (n = 1). A total of 28 studies applied probability sampling (random sampling, systematic sampling, stratified sampling, clustered sampling, and multistage sampling), 54 studies applied non-probability sampling (convenience sampling, quota sampling, purposive sampling, and snowball sampling), and 90 studies did not provide the sampling method (Supplementary Table 1).
Subgroup analysis involved the six regions in the world (African, American, Eastern Mediterranean, European, South-East Asian, and Western Pacific), population (college students, general adult population, healthcare workers, high-risk population, and parents and caregivers), gender, vaccines effectiveness (at 90 and 95%), and survey time.
Risk of Bias in Studies
The J.B.I. quality assessment showed that 60 studies were at low risk of bias, 47 studies were at moderate bias, and 65 studies were at high risk of bias (Supplementary Table 2). All the studies were included. The pooled proportion of COVID-19 vaccines acceptance for the studies with low, moderate, and high risk of bias were 0.59 (95% CI: 0.54, 0.65), 0.61 (95% CI: 0.57, 0.66) and 0.63 (95% CI: 0.58, 0.68), respectively.
Results of Total and Subgroup Studies
In Table 1, the total estimated proportion by COVID-19 vaccines acceptance pooled from 170 studies was 0.61 (95% CI: 0.59,0.64). The estimated pooled proportion by study designs of cohort study, cross sectional study, descriptive study, longitudinal study and combination study of longitudinal and cross-sectional were 0.77 (95% CI: 0.73, 0.81), 0.60 (95% CI: 0.57, 0.63), 0.69 (95% CI: 0.62, 0.75), 0.64 (95% CI: 0.49, 0.78) and 0.39 (95% CI: 0.37, 0.40) respectively. Meanwhile, the pooled proportion for probability sampling studies was 0.61 (95% CI: 0.55, 0.67) and 0.62 (95% CI: 0.57, 0.66) for non-probability sampling studies.
Table 1
| Outcome | No. of studies | Proportion (95% CI) | I2 (%) | p-valuea | I2 diff (%) | p-valuea | |
|---|---|---|---|---|---|---|---|
| Vaccines acceptance | 170 | 0.61 (0.59, 0.64) | 100 | p < 0.001 | |||
| Subgroup: | |||||||
| Study designs | Total | 170 | 0.61 (0.59, 0.64) | 100 | p < 0.001 | 99.1 | p < 0.001 |
| Cohort | 4 | 0.77 (0.73, 0.81) | 90 | p < 0.001 | |||
| Cross sectional | 138 | 0.60 (0.57, 0.63) | 100 | p < 0.001 | |||
| Descriptive | 23 | 0.69 (0.62, 0.75) | 100 | p < 0.001 | |||
| Longitudinal | 4 | 0.64 (0.49, 0.78) | 99 | p < 0.001 | |||
| Combination | 1 | 0.39 (0.37, 0.40) | NA | NA | |||
| Sampling methods | Total | 81 | 0.61 (0.58, 0.65) | 100 | p < 0.001 | 0 | 0.82 |
| Probability | 27 | 0.61 (0.55, 0.67) | 100 | p < 0.001 | |||
| Non-probability | 54 | 0.62 (0.57, 0.66) | 100 | p < 0.001 | |||
| Regions | Total | 165 | 0.62 (0.59, 0.64) | 100 | p < 0.001 | 71.5 | 0.004 |
| African | 15 | 0.53 (0.39, 0.67) | 100 | p < 0.001 | |||
| American | 35 | 0.62 (0.57, 0.67) | 100 | p < 0.001 | |||
| Eastern Mediterranean | 33 | 0.52 (0.45, 0.59) | 100 | p < 0.001 | |||
| European | 46 | 0.65 (0.59, 0.71) | 100 | p < 0.001 | |||
| South-East Asian | 9 | 0.74 (0.64, 0.84) | 100 | p < 0.001 | |||
| Western Pacific | 32 | 0.66 (0.60, 0.73) | 100 | p < 0.001 | |||
| Population | Total | 170 | 0.61 (0.59, 0.64) | 100 | p < 0.001 | 0 | 0.66 |
| College students | 15 | 0.62 (0.52, 0.73) | 100 | p < 0.001 | |||
| General adult | 105 | 0.61 (0.58, 0.65) | 100 | p < 0.001 | |||
| Healthcare workers | 33 | 0.63 (0.56, 0.71) | 100 | p < 0.001 | |||
| High risks | 23 | 0.61 (0.52, 0.70) | 100 | p < 0.001 | |||
| Parents and caregivers | 7 | 0.52 (0.40, 0.65) | 99 | p < 0.001 | |||
| Gender | Total | 89 | 0.60 (0.56, 0.65) | 100 | p < 0.001 | 44.8 | 0.18 |
| Male | 89 | 0.64 (0.57, 0.71) | 100 | p < 0.001 | |||
| Female | 89 | 0.57 (0.48, 0.65) | 100 | p < 0.001 | |||
| Vaccines effectiveness | Total | 6 | 0.71 (0.63, 0.79) | 100 | p < 0.001 | 36.5 | 0.21 |
| At 90% effective | 3 | 0.62 (0.40, 0.84) | 100 | p < 0.001 | |||
| At 95% effective | 5 | 0.77 (0.69, 0.85) | 100 | p < 0.001 | |||
| Survey time | Total | 7 | 0.65 (0.54, 0.75) | 100 | p < 0.001 | 0 | 0.64 |
| First survey | 7 | 0.68 (0.56, 0.79) | 99 | p < 0.001 | |||
| Second survey | 7 | 0.62 (0.43, 0.81) | 100 | p < 0.001 | |||
The outcome measures of COVID-19 vaccines acceptance.
Test for overall effect.
By subgroup analyses, the total proportion by regions was [0.62 (95% CI: 0.59, 0.64)] pooled from 165 studies, and the region with the highest proportion of COVID-19 vaccines acceptance was in South-East Asia [0.74 (95% CI: 0.64, 0.84)] which pooled from nine studies and the lowest vaccines acceptance was in Eastern Mediterranean [0.52 (95% CI: 0.45, 0.59)]. The total proportion by population was pooled from 170 studies [0.61 (95% CI: 0.59, 0.64)]. Population comparison showed that the proportion of COVID-19 vaccines acceptance was similar, which range 0.61 to 0.63 among college students, general adults, healthcare workers, and high-risk populations. However, the population of parents and caregivers was the lowest in the proportion of COVID-19 vaccines acceptance [0.52 (95% CI: 0.40, 0.65)].
The pooled proportion of COVID-19 vaccines acceptance by gender from 89 studies was [0.60 (95% CI: 0.56, 0.65)] and was higher in male [0.64 (95% CI: 0.57, 0.71)] compared to female [0.57 (95% CI: 0.48, 0.65)]. The 95% vaccines effectiveness showed higher in proportion of COVID-19 vaccines acceptance [0.77 (95% CI: 0.69, 0.85)] compared to 90% of vaccines effective [0.62 (95% CI: 0.40, 0.84)] with the total proportion by vaccines effectiveness was [0.71 (95% CI: 0.63, 0.79)] from six studies. The total pooled proportion from seven studies by survey time was 0.65 (95% CI: 0.54, 0.75). The proportion of COVID-19 vaccines acceptance was reduced in the second survey [0.62 (95% CI:0.43, 0.81)] compared to the first survey [0.68 (95% CI: 0.56, 0.79)]. In China and Australia, the surveys were repeated based on two epidemic phases, namely severe epidemic phase and well-contained phase (149, 171, 172). A study in Saudi Arabia performed the survey before and after the interim report of the efficacy rate of the RNA BNT162b2 vaccine (94).
All data for each outcome measure had considerable heterogeneity by the random-effects model (I2 > 99%). The heterogeneity of subgroups differences showed that the acceptance of the vaccine was with considerable heterogeneity; substantial heterogeneity for regions, moderate heterogeneity for gender and vaccines effectiveness. Heterogeneity might not be important for population and survey time (Table 1). The results were also presented in forest plots (Supplementary Figures 1–8).
Discussion
Vaccination is an essential approach for tackling the COVID-19 pandemic by achieving herd immunity in the population. The effectiveness of this approach depends on vaccination acceptance in the population. In the current review, the pooled proportion of COVID-19 vaccine acceptance from 170 studies worldwide involving 50 countries was 61% (95% CI: 59, 64%). This finding was lower compared to a previous estimate of COVID-19 vaccine acceptance [73.31% (95% CI: 70.52%, 76.01%)], which involved 38 studies across 36 countries with limited data from low-income countries (186). Concerns about the vaccine's safety, efficacy, and side effects, trust in the government or related authorities (186), and religious beliefs (187) were primary factors that influenced vaccine acceptance. The subgroup analyses of this current review also determined variability in vaccine acceptance, which ranged from 52 to 77%.
The pooled proportion of COVID-19 vaccine acceptance among regions ranged from 52 to 74%, with Southeast Asia the highest and the Eastern Mediterranean the lowest. This result was supported by a review that reported vaccine acceptance of over 90% in Southeast Asia and the lowest proportions of acceptance in Middle East countries, with < 30% in Kuwait and Jordan (187). The low vaccine acceptance in the Middle East was related to widespread beliefs in conspiracies that negatively affected vaccination (188). Nevertheless, this current review also saw low vaccine acceptance in the African region. A study in Nigeria revealed that besides geographical location, which was associated with low vaccine acceptance, the other plausible reasons for this situation were low education levels, which led to poor health literacy, distrust in vaccines and the government, and cultural and religious beliefs, among others (18).
Vaccination acceptance was also higher in males than in females, which is in line with other reviews (187, 189). It was reported that males were less likely to believe conspiracy theories and more likely to perceive COVID-19 as dangerous (127). Females were found to express more concerns about the safety of vaccines and distrust in the quality and impartiality of vaccine information provided by healthcare professionals (190). However, a study with a higher proportion of females who accepted the COVID-19 vaccine reported that they perceived that vaccination was for the safety of families and communities. Widespread vaccination coverage could allow them to return to the previous work of routines and childcare arrangements (191).
The pooled proportion of COVID-19 vaccine acceptance for the population groups varied from 52 to 63%. Unsurprisingly, healthcare workers showed the highest proportion of vaccine acceptance. Since healthcare workers were among the first to receive COVID-19 vaccines, their attitude or perception toward COVID-19 vaccines would affect the other population's decisions to recommend the vaccination to friends, families, and their patients (192). Similar proportions (61 to 62%) were also seen in college students, the general adult public, and high-risk populations. As reported by other studies, challenges threatening vaccination uptake in a population include media misinformation, especially from social media (189), and widely broadcast rumors, myths, and inaccurate beliefs regarding vaccines by the anti-vaccine community (193). Confusing information may affect people's awareness of vaccination, especially those who lack sufficient knowledge concerning COVID-19 vaccines (194). For parents and caregivers, the proportion who accepted vaccination for their children was low (52%), and this might be influenced by insufficient clinical data on vaccine safety and efficacy on children (181) and their concern that young children are likelier to suffer side effects (195). Many COVID-19 vaccines are still not approved for children younger than 12, so parents may think vaccines are unsafe for young children.
The decision to accept COVID-19 vaccination was also influenced by vaccine effectiveness (196); this review showed that people were willing to take vaccines with higher efficacy. The interim result of a living systematic review showed that the effectiveness of the COVID-19 vaccine after one dose varied between 16.9 and 91.2%. While the effectiveness increased to between 61.7 and 98.6% after completing the second dose (197). However, insufficient evidence for COVID-19 vaccine effectiveness has been reported as a leading reason for reduced confidence in vaccines among the general population (37, 185).
The time during which the survey was conducted showed that the acceptance of the COVID-19 vaccine changed over time. All the studies showed evidence that the COVID-19 vaccine acceptance changed over time. The proportion of vaccine acceptance was reduced in the second survey. A global review of vaccine acceptance also showed a similar pattern. In a review, countries such as France, Italy, and China established a decreased proportion of vaccine acceptance in their second and third surveys.
Conversely, the United States showed an increased pattern of vaccine acceptance in the second and third surveys. The situation was different in the United Kingdom, which showed that the proportion was high in the first survey, increased further in the second survey, and then decreased for the third and fourth surveys before increasing again in the fifth survey. Still, in the fifth survey, the proportion of vaccine acceptance was not as high as in the first survey (187). It has also been reported that reduced vaccine acceptance is related to increased serious side effects of the vaccines (196).
Media and public service messaging, particularly fear appraisal-framed public service messages compared to safety benefits public service messages, influence willingness to obtain the COVID-19 vaccine. However, conspiracy theories circulated in the media by vaccination-averse people about vaccine side effects impact people's decision to get vaccinated (198). The hesitation in vaccination may be due to overestimating perceived risk in the COVID-19 pandemic, messaging fatigue, and desensitization caused by repeated exposure to information. Consequently, overloading information especially social media confuses people and impairs their ability to differentiate between reliable sources and incorrect information (189).
Limitations of the Review
The search was limited to articles published in English only due to limited time, human, and financial resources to translate works published in other languages; this may have limited this review's generalizability. To have a more comprehensive assessment of the data, the authors decided to include all the available studies regardless of whether the quality of the data was low, moderate, or high, based on the assessment of the risk of bias. Furthermore, most of the research studies included in this review were cross-sectional studies, which can be thought of as visuals of vaccine hesitancy status in each country/region. They have different sampling strategies, which may explain some of the differences in vaccine acceptance rates reported in different studies from the same country. As a result, the findings should be regarded with caution, as they are unable to forecast future changes in vaccine acceptance rates. The other limitation was the sole dependence on the MEDLINE (PubMed) database in the search study. MEDLINE was reported as the best single source for retrieval of a systematic review, with an 89.7% inclusion rate that provided free-of-charge and open-access articles (199). However, it is also recommended to search extensively for studies using several databases to reduce possible biases in the included studies.
Conclusion
The rate of COVID-19 vaccine acceptance varied by region, population type, gender, vaccine effectiveness, and survey time, with an overall pooled proportion of 61%. A high level of acceptance of vaccination is required to achieve herd immunity for the disease. Many vaccination campaigns and programs are available globally to enhance public awareness to access and accept the COVID-19 vaccine to reach herd immunity and control the pandemic.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.
Author contributions
RCY and MNN: conceptualization, methodology, and validation. RCY: software, formal analysis, data curation, and writing—original draft preparation. MNN and RCY: writing—review and editing. MNN and YMA: visualization and supervision. All authors have read and agreed to the published version of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.783982/full#supplementary-material
Supplementary Figure 1Forest plots of vaccines acceptance.
Supplementary Figure 2Forest plots of vaccines acceptance by study designs.
Supplementary Figure 3Forest plots of vaccines acceptance by sampling methods.
Supplementary Figure 4Forest plots of vaccines acceptance by regions.
Supplementary Figure 5Forest plots of vaccines acceptance by population.
Supplementary Figure 6Forest plots of vaccines acceptance by gender.
Supplementary Figure 7Forest plots of vaccines acceptance by vaccines effectiveness.
Supplementary Figure 8Forest plots of vaccines acceptance by survey time.
Supplementary Table 1Characteristics of the included studies.
Supplementary Table 2J.B.I Critical appraisal checklist for studies reporting prevalence data.
References
1.
WHO. Weekly Epidemiological Update On COVID-19-31 August 2021. Edition 55 ed. World Health Organization (2021).
2.
WHO. Tracking SARS-CoV-2 Variants. World Health Organization (2021).
3.
WHO. Status of COVID-19 Vaccines Within WHO EUL/PQ Evaluation Process. World Health Organization (2021).
4.
Mayo. Herd Immunity and COVID-19 (coronavirus): What You Need To Know. Mayo Foundation for Medical Education and Research (MFMER). (2021). Available online at: https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/herd-immunity-and-coronavirus/art-20486808 (accessed July 14, 2021).
5.
Syed AlwiSARRafidahEZurrainiAJuslinaOBrohiIBLukasS. A survey on COVID-19 vaccine acceptance and concern among Malaysians. BMC Public Health. (2021) 21:1129. 10.1186/s12889-021-11071-6
6.
LazarusJVRatzanSCPalayewAGostinLOLarsonHJRabinKet al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. (2021) 27:225–8. 10.1038/s41591-020-1124-9
7.
MalikAAMcFaddenSMElharakeJOmerSB. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. (2020) 26:100495. 10.1016/j.eclinm.2020.100495
8.
Al-MohaithefMPadhiBK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: A web-based national survey. J Multidiscip Healthc. (2020) 13:1657–63. 10.2147/JMDH.S276771
9.
HouZTongYDuFLuLZhaoSYuKet al. Assessing COVID-19 vaccine hesitancy, confidence, and public engagement: a global social listening study. J Med Internet Res. (2021) 23:e27632. 10.2196/27632
10.
QunaibiEAHelmyMBashetiISultanI. A high rate of COVID-19 vaccine hesitancy in a large-scale survey on Arabs. Elife. (2021) 10:e68038. 10.7554/eLife.68038
11.
MoherDLiberatiATetzlaffJAltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. (2009) 339:b2535. 10.1136/bmj.b2535
12.
AromatarisEMunnZ. JBI Manual For Evidence Synthesis. (2020). Available online at: https://synthesismanual.jbi.global. 10.46658/JBIMES-20-01
13.
Review Manager (RevMan). 5.4.1. The Cochrane Collaboration (2020).
14.
HigginsJThomasJChandlerJCumpstonMLiTPageMet al. Cochrane Handbook For Systematic Reviews Of Interventions Version 6.2. Cochrane. (2021). Available online at: www.training.cochrane.org/handbook (accessed February 2021).
15.
MunnZMoolaSLisyKRiitanoDTufanaruC. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. (2015) 13:147–53. 10.1097/XEB.0000000000000054
16.
Cristina da Silva RosaBHernandez Alves Ribeiro CésarCPParanhosLRGuedes-GranzottiRBLewisDR. Speech-language disorders in children with congenital Zika virus syndrome: a systematic review. Int J Pediatr Otorhinolaryngol. (2020) 138:110309. 10.1016/j.ijporl.2020.110309
17.
AbebeHShituSMoseA. Understanding of COVID-19 vaccine knowledge, attitude, acceptance, and determinates of COVID-19 vaccine acceptance among adult population in Ethiopia. Infect Drug Resist. (2021) 14:2015–25. 10.2147/IDR.S312116
18.
AdebisiYAAlaranAJBolarinwaOAAkande-SholabiWLucero-PrisnoDE. When it is available, will we take it? social media users' perception of hypothetical COVID-19 vaccine in Nigeria. Pan Afr Med J. (2021) 38:230. 10.11604/pamj.2021.38.230.27325
19.
AdeniyiOVSteadDSingata-MadlikiMBattingJWrightMJellimanEet al. Acceptance of COVID-19 vaccine among the healthcare workers in the Eastern Cape, South Africa: a cross sectional study. Vaccines. (2021) 9:6. 10.3390/vaccines9060666
20.
BongominFOlumRAndia-BiraroINakwagalaFNHassanKHNassoziDRet al. COVID-19 vaccine acceptance among high-risk populations in Uganda. Ther Adv Infect Dis. (2021) 8:20499361211024376. 10.1177/20499361211024376
21.
DingaJNSindaLKTitanjiVPK. Assessment of vaccine hesitancy to a COVID-19 vaccine in cameroonian adults and its global implication. Vaccines. (2021) 9:2. 10.3390/vaccines9020175
22.
DitekemenaJDNkambaDMMutwadiAMavokoHMSiewe FodjoJNLuhataCet al. COVID-19 vaccine acceptance in the democratic Republic of Congo: a cross-sectional survey. Vaccines. (2021) 9:2. 10.3390/vaccines9020153
23.
EchoruIAjamboPDKeiraniaEBukenyaEEM. Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda. BMC Public Health. (2021) 21:1106. 10.1186/s12889-021-11197-7
24.
HandeboSWoldeMShituKKassieA. Determinant of intention to receive COVID-19 vaccine among school teachers in Gondar City, Northwest Ethiopia. PLoS ONE. (2021) 16:e0253499. 10.1371/journal.pone.0253499
25.
Kabamba NzajiMKabamba NgombeLNgoie MwambaGBanza NdalaDBMbidi MiemaJLuhata LungoyoCet al. Acceptability of vaccination against COVID-19 among healthcare workers in the democratic Republic of the Congo. Pragmat Obs Res. (2020) 11:103–9. 10.2147/POR.S271096
26.
KanyikeAMOlumRKajjimuJOjilongDAkechGMNassoziDRet al. Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. Trop Med Health. (2021) 49:37. 10.1186/s41182-021-00331-1
27.
LampteyESerwaaDAppiahAB. A nationwide survey of the potential acceptance and determinants of COVID-19 vaccines in Ghana. Clin Exp Vaccine Res. (2021) 10:183–90. 10.7774/cevr.2021.10.2.183
28.
MeseleM. COVID-19 vaccination acceptance and its associated factors in Sodo Town, Wolaita Zone, Southern Ethiopia: cross-sectional study. Infect Drug Resist. (2021) 14:2361–7. 10.2147/IDR.S320771
29.
MoseAYeshanehA. COVID-19 vaccine acceptance and its associated factors among pregnant women attending antenatal care clinic in Southwest Ethiopia: institutional-based cross-sectional study. Int J Gen Med. (2021) 14:2385–95. 10.2147/IJGM.S314346
30.
ZewudeBHabtegiorgisT. Willingness to take COVID-19 vaccine among people most at risk of exposure in Southern Ethiopia. Pragmat Obs Res. (2021) 12:37–47. 10.2147/POR.S313991
31.
Alvarado-SocarrasJLVesga-VarelaALQuintero-LesmesDCFama-PereiraMMSerrano-DiazNCVascoMet al. Perception of COVID-19 vaccination amongst physicians in Colombia. Vaccines. (2021) 9:3. 10.3390/vaccines9030287
32.
CarmodyERZanderDKleinEJMulliganMJCaplanAL. Knowledge and attitudes toward COVID-19 and vaccines among a New York Haredi-Orthodox Jewish community. J Community Health. (2021) 46:1161–9. 10.1007/s10900-021-00995-0
33.
CerdaAAGarcíaLY. Hesitation and refusal factors in individuals' decision-making processes regarding a Coronavirus Disease 2019 vaccination. Front Public Health. (2021) 9:626852. 10.3389/fpubh.2021.626852
34.
DubéÈDionneMPelletierCHamelDGadioS. COVID-19 vaccination attitudes and intention among Quebecers during the first and second waves of the pandemic: findings from repeated cross-sectional surveys. Hum Vaccin Immunother. (2021) 17:3922–32. 10.1080/21645515.2021.1947096
35.
EhdeDMRobertsMKHerringTEAlschulerKN. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States. Mult Scler Relat Disord. (2021) 49:102788. 10.1016/j.msard.2021.102788
36.
FisherKABloomstoneSJWalderJCrawfordSFouayziHMazorKM. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults. Ann Intern Med. (2020) 173:964–73. 10.7326/M20-3569
37.
GatwoodJMcKnightMFiscusMHohmeierKCChisholm-BurnsM. Factors influencing likelihood of COVID-19 vaccination: a survey of Tennessee adults. Am J Health Syst Pharm. (2021) 78:879–89. 10.1093/ajhp/zxab099
38.
HetheringtonEEdwardsSAMacDonaldSERacineNMadiganSMcDonaldSet al. SARS-CoV-2 vaccination intentions among mothers of children aged 9 to 12 years: a survey of the all our families cohort. CMAJ Open. (2021) 9:E548–55. 10.9778/cmajo.20200302
39.
Jaramillo-MongeJObimpehMVegaBAcurioDBovenAVerhoevenVet al. COVID-19 vaccine acceptance in Azuay Province, Ecuador: a cross-sectional online survey. Vaccines. (2021) 9:6. 10.3390/vaccines9060678
40.
JohnsonKDAkingbolaOAndersonJHartJChappleAWoodsCet al. Combatting a “Twin-demic”: A quantitative assessment of COVID-19 and influenza vaccine hesitancy in primary care patients. Health Promot Perspect. (2021) 11:179–85. 10.34172/hpp.2021.22
41.
KelkarAHBlakeJACherabuddiKCornettHMcKeeBLCogleCR. Vaccine enthusiasm and hesitancy in cancer patients and the impact of a webinars. Healthcare. (2021) 9:3. 10.3390/healthcare9030351
42.
KuterBJBrowneSMomplaisirFMFeemsterKAShenAKGreen-McKenzieJet al. Perspectives on the receipt of a COVID-19 vaccine: a survey of employees in two large hospitals in Philadelphia. Vaccine. (2021) 39:1693–700. 10.1016/j.vaccine.2021.02.029
43.
LuciaVCKelekarAAfonsoNM. COVID-19 vaccine hesitancy among medical students. J Public Health. (2020) 43:445-9. 10.1093/pubmed/fdaa230
44.
MascarenhasAKLuciaVCKelekarAAfonsoNM. Dental students' attitudes and hesitancy toward COVID-19 vaccine. J Dent Educ. (2021). 10.1002/jdd.12632
45.
NikolovskiJKoldijkMWeverlingGJSpertusJTurakhiaMSaxonLet al. Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. PLoS ONE. (2021) 16:e0251963. 10.1371/journal.pone.0251963
46.
OlanipekunTAbeTEffoeVKagbo-KueSChinekeIIvonyeCet al. Attitudes and perceptions towards Coronavirus Disease 2019 (COVID-19) vaccine acceptance among recovered African American patients. J Gen Intern Med. (2021) 36:2186–8. 10.1007/s11606-021-06787-5
47.
ParenteDJOjoAGurleyTLeMasterJWMeyerMWildDMet al. Acceptance of COVID-19 vaccination among health system personnel. J Am Board Fam Med. (2021) 34:498–508. 10.3122/jabfm.2021.03.200541
48.
Piltch-LoebRSavoiaEGoldbergBHughesBVerheyTKayyemJet al. Examining the effect of information channel on COVID-19 vaccine acceptance. PLoS ONE. (2021) 16:e0251095. 10.1371/journal.pone.0251095
49.
PogueKJensenJLStancilCKFergusonDGHughesSJMelloEJet al. Influences on attitudes regarding potential COVID-19 vaccination in the United States. Vaccines. (2020) 8:4. 10.3390/vaccines8040582
50.
RaceyCSDonkenRPorterIAlbertABettingerJAMarkJet al. Intentions of public school teachers in British Columbia, Canada to receive a COVID-19 vaccine. Vaccine: X. (2021) 8:100106. 10.1016/j.jvacx.2021.100106
51.
ReiterPLPennellMLKatzML. Acceptability of a COVID-19 vaccine among adults in the United States: how many people would get vaccinated?Vaccine. (2020) 38:6500–7. 10.1016/j.vaccine.2020.08.043
52.
SalmonDADudleyMZBrewerJKanLGerberJEBudiganHet al. COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization. Vaccine. (2021) 39:2698–711. 10.1016/j.vaccine.2021.03.034
53.
SharmaMDavisREWilkersonAH. COVID-19 vaccine acceptance among college students: a theory-based analysis. Int J Environ Res Public Health. (2021) 18:9. 10.3390/ijerph18094617
54.
ShawJStewartTAndersonKBHanleySThomasSJSalmonDAet al. Assessment of U.S. health care personnel (HCP) attitudes towards COVID-19 vaccination in a large university health care system. Clin Infect Dis. (2021) 73:1776–83. 10.1093/cid/ciab054
55.
ShekharRSheikhABUpadhyaySSinghMKottewarSMirHet al. COVID-19 vaccine acceptance among health care workers in the United States. Vaccines. (2021) 9:2. 10.3390/vaccines9020119
56.
ShihSFWagnerALMastersNBProsserLALuYZikmund-FisherBJ. Vaccine hesitancy and rejection of a vaccine for the novel Coronavirus in the United States. Front Immunol. (2021) 12:558270. 10.3389/fimmu.2021.558270
57.
SternMFPiaseckiAMStrickLBRajeshwarPTyagiEDolovichSet al. Willingness to receive a COVID-19 vaccination among incarcerated or detained persons in correctional and detention facilities - four states, September-December 2020. MMWR Morb Mortal Wkly Rep. (2021) 70:473–7. 10.15585/mmwr.mm7013a3
58.
TsapepasDHusainSAKingKLBurgosYCohenDJMohanS. Perspectives on COVID-19 vaccination among kidney and pancreas transplant recipients living in New York City. Am J Health Syst Pharm. (2021) 78:2040–5. 10.1093/ajhp/zxab272
59.
Urrunaga-PastorDBendezu-QuispeGHerrera-AñazcoPUyen-CaterianoAToro-HuamanchumoCJRodriguez-MoralesAJet al. Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean. Travel Med Infect Dis. (2021) 41:102059. 10.1016/j.tmaid.2021.102059
60.
ViswanathKBekaluMDhawanDPinnamaneniRLangJMcLoudR. Individual and social determinants of COVID-19 vaccine uptake. BMC Public Health. (2021) 21:818. 10.1186/s12889-021-10862-1
61.
XiangXMHollenCYangQBrumbachBHSpainRIWooliscroftL. COVID-19 vaccination willingness among people with multiple sclerosis. Mult Scler J Exp Transl Clin. (2021) 7:20552173211017159. 10.1177/20552173211017159
62.
YangYDobalianAWardKD. COVID-19 vaccine hesitancy and its determinants among adults with a history of tobacco or marijuana use. J Community Health. (2021) 46:1090–8. 10.1007/s10900-021-00993-2
63.
KhubchandaniJSharmaSPriceJHWiblishauserMJSharmaMWebbFJ. COVID-19 vaccination hesitancy in the United States: a rapid national assessment. J Community Health. (2021) 46:270–7. 10.1007/s10900-020-00958-x
64.
Abu-FarhaRMukattashTItaniRKaroutSKhojahHAl-MahmoodAet al. Willingness of Middle Eastern public to receive COVID-19 vaccines. Saudi Pharm J. (2021) 29:734-9. 10.1016/j.jsps.2021.05.005
65.
AhmedMAMColebundersRGeleAAFarahAAOsmanSGuledIAet al. COVID-19 vaccine acceptability and adherence to preventive measures in Somalia: results of an online survey. Vaccines. (2021) 9:6. 10.3390/vaccines9060543
66.
AlabdullaMReaguSMAl-KhalAElzainMJonesRM. COVID-19 vaccine hesitancy and attitudes in Qatar: a national cross-sectional survey of a migrant-majority population. Influenza Other Respir Viruses. (2021) 15:361–70. 10.1111/irv.12847
67.
AlAwadhiEZeinDMallallahFBin HaiderNHossainA. Monitoring COVID-19 vaccine acceptance in Kuwait during the pandemic: results from a national serial study. Risk Manag Healthc Policy. (2021) 14:1413–29. 10.2147/RMHP.S300602
68.
AlfageehEIAlshareefNAngawiKAlhazmiFChirwaGC. Acceptability of a COVID-19 vaccine among the Saudi population. Vaccines. (2021) 9:3. 10.3390/vaccines9030226
69.
Al-MarshoudiSAl-BalushiHAl-WahaibiAAl-KhaliliSAl-MaaniAAl-FarsiNet al. Knowledge, attitudes, and practices (KAP) toward the COVID-19 vaccine in Oman: a pre-campaign cross-sectional study. Vaccines. (2021) 9:6. 10.3390/vaccines9060602
70.
Al-MetwaliBZAl-JumailiAAAl-AlagZASorofmanB. Exploring the acceptance of COVID-19 vaccine among healthcare workers and general population using health belief model. J Eval Clin Pract. (2021) 27:1112–22. 10.1111/jep.13581
71.
Al-MistarehiAHKheirallahKAYassinAAlomariSAledrisiMKBani AtaEMet al. Determinants of the willingness of the general population to get vaccinated against COVID-19 in a developing country. Clin Exp Vaccine Res. (2021) 10:171–82. 10.7774/cevr.2021.10.2.171
72.
Al-MullaRAbu-MadiMTalafhaQMTayyemRFAbdallahAM. COVID-19 vaccine hesitancy in a representative education sector population in Qatar. Vaccines. (2021) 9:6. 10.3390/vaccines9060665
73.
AlobaidiS. Predictors of intent to receive the COVID-19 vaccination among the population in the Kingdom of Saudi Arabia: a survey study. J Multidiscip Healthc. (2021) 14:1119–28. 10.2147/JMDH.S306654
74.
Al-QeremWAJarabAS. COVID-19 vaccination acceptance and its associated factors among a Middle Eastern population. Front Public Health. (2021) 9:632914. 10.3389/fpubh.2021.632914
75.
AlqudeimatYAleneziDAlHajriBAlfouzanHAlmokhaizeemZAltamimiSet al. Acceptance of a COVID-19 vaccine and its related determinants among the general adult population in Kuwait. Med Princ Pract. (2021) 30:262–71. 10.1159/000514636
76.
Al-SanafiMSallamM. Psychological determinants of COVID-19 vaccine acceptance among healthcare workers in Kuwait: a cross-sectional study using the 5C and vaccine conspiracy beliefs scales. Vaccines. (2021) 9:7. 10.3390/vaccines9070701
77.
AlshahraniSMDehomSAlmutairiDAlnasserBSAlsaifBAlabdrabalnabiAAet al. Acceptability of COVID-19 vaccination in Saudi Arabia: a cross-sectional study using a web-based survey. Hum Vaccin Immunother. (2021) 17:3338–47. 10.1080/21645515.2021.1936869
78.
BaghdadiLRAlghaihbSGAbuhaimedAAAlkelabiDMAlqahtaniRS. Healthcare workers' perspectives on the upcoming COVID-19 vaccine in terms of their exposure to the influenza vaccine in Riyadh, Saudi Arabia: a cross-sectional study. Vaccines. (2021) 9:5. 10.3390/vaccines9050465
79.
ChaudharyFAAhmadBKhalidMDFazalAJavaidMMButtDQ. Factors influencing COVID-19 vaccine hesitancy and acceptance among the Pakistani population. Hum Vaccin Immunother. (2021) 17:3365–70. 10.1080/21645515.2021.1944743
80.
DrorAADaoudAMorozovNGLayousEEisenbachNMizrachiMet al. Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification. Eur J Epidemiol. (2021) 36:709–14. 10.1007/s10654-021-00758-0
81.
DrorAAEisenbachNTaiberSMorozovNGMizrachiMZigronAet al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. (2020) 35:775–9. 10.1007/s10654-020-00671-y
82.
El-ElimatTAbuAlSamenMMAlmomaniBAAl-SawalhaNAAlaliFQ. Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. PLoS ONE. (2021) 16:e0250555. 10.1371/journal.pone.0250555
83.
ElhadiMAlsoufiAAlhadiAHmeidaAAlshareeaEDokaliMet al. Knowledge, attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine: a cross-sectional study. BMC Public Health. (2021) 21:955. 10.1186/s12889-021-10987-3
84.
FaresSElmnyerMMMohamedSSElsayedR. COVID-19 vaccination perception and attitude among healthcare workers in Egypt. J Prim Care Community Health. (2021) 12:21501327211013303. 10.1177/21501327211013303
85.
Kasrine Al HalabiCObeidSSacreHAkelMHallitRSalamehPet al. Attitudes of Lebanese adults regarding COVID-19 vaccination. BMC Public Health. (2021) 21:998. 10.1186/s12889-021-10902-w
86.
MaraqaBNazzalZRabiRSarhanNAl-ShakhraKAl-KailaM. COVID-19 vaccine hesitancy among health care workers in Palestine: a call for action. Prev Med. (2021) 149:106618. 10.1016/j.ypmed.2021.106618
87.
MohamadOZamloutAAlKhouryNMazloumAAAlsalkiniMShaabanR. Factors associated with the intention of Syrian adult population to accept COVID19 vaccination: a cross-sectional study. BMC Public Health. (2021) 21:1310. 10.1186/s12889-021-11361-z
88.
QattanAMNAlshareefNAlsharqiOAl RahahlehNChirwaGCAl-HanawiMK. Acceptability of a COVID-19 vaccine among healthcare workers in the Kingdom of Saudi Arabia. Front Med. (2021) 8:644300. 10.3389/fmed.2021.644300
89.
RabiRMaraqaBNazzalZZinkT. Factors affecting nurses' intention to accept the COVID-19 vaccine: a cross-sectional study. Public Health Nurs. (2021). 10.1111/phn.12907
90.
SaiedSMSaiedEMKabbashIAAbdoSAE. Vaccine hesitancy: beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students. J Med Virol. (2021) 93:4280–91. 10.1002/jmv.26910
91.
SallamMDababsehDEidHAl-MahzoumKAl-HaidarATaimDet al. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among other Arab countries. Vaccines. (2021) 9:1. 10.3390/vaccines9010042
92.
SallamMDababsehDEidHHasanHTaimDAl-MahzoumKet al. Low COVID-19 vaccine acceptance is correlated with conspiracy beliefs among university students in Jordan. Int J Environ Res Public Health. (2021) 18:5. 10.3390/ijerph18052407
93.
ShmueliL. Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model. BMC Public Health. (2021) 21:804. 10.1186/s12889-021-10816-7
94.
TemsahMHBarryMAljamaanFAlhuzaimiAAl-EyadhyASaddikBet al. Adenovirus and RNA-based COVID-19 vaccines' perceptions and acceptance among healthcare workers in Saudi Arabia: a national survey. BMJ Open. (2021) 11:e048586. 10.1136/bmjopen-2020-048586
95.
KhaledSMPetcuCBaderLAmroIAl-HamadiAAl AssiMet al. Prevalence and potential determinants of COVID-19 vaccine hesitancy and resistance in Qatar: results from a nationally representative survey of Qatari nationals and migrants between December 2020 and January 2021. Vaccines. (2021) 9:5. 10.3390/vaccines9050471
96.
AbuownAEllisTMillerJDavidsonRKachwalaQMedeirosMet al. COVID-19 vaccination intent among London healthcare workers. Occup Med. (2021) 71:211-4. 10.1093/occmed/kqab057
97.
BabickiMMastalerz-MigasA. Attitudes toward vaccination against COVID-19 in Poland. a longitudinal study performed before and two months after the commencement of the population vaccination programme in Poland. Vaccines. (2021) 9:5. 10.3390/vaccines9050503
98.
BendauAPlagJPetzoldMBStröhleA. COVID-19 vaccine hesitancy and related fears and anxiety. Int Immunopharmacol. (2021) 97:107724. 10.1016/j.intimp.2021.107724
99.
Blanchard-RohnerGCaprettiniBRohnerDVothHJ. Impact of COVID-19 and intensive care unit capacity on vaccination support: Evidence from a two-leg representative survey in the United Kingdom. J Virus Erad. (2021) 7:100044. 10.1016/j.jve.2021.100044
100.
ButterSMcGlincheyEBerryEArmourC. Psychological, social, and situational factors associated with COVID-19 vaccination intentions: a study of UK key workers and non-key workers. Br J Health Psychol. (2021) 27:13–29. 10.1111/bjhp.12530
101.
Del RiccioMBoccaliniSRigonLBiamonteMAAlboraGGiorgettiDet al. Factors influencing SARS-CoV-2 vaccine acceptance and hesitancy in a population-based sample in Italy. Vaccines. (2021) 9:6. 10.3390/vaccines9060633
102.
DetocMBruelSFrappePTardyBBotelho-NeversEGagneux-BrunonA. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. (2020) 38:7002–6. 10.1016/j.vaccine.2020.09.041
103.
Di GennaroFMurriRSegalaFVCerrutiLAbdulleASaracinoAet al. Attitudes towards Anti-SARS-CoV2 vaccination among healthcare workers: results from a national survey in Italy. Viruses. (2021) 13:3. 10.3390/v13030371
104.
Di GiuseppeGPelulloCPDella PollaGPaviaMAngelilloIF. Exploring the willingness to accept SARS-CoV-2 vaccine in a university population in Southern Italy, September to November 2020. Vaccines. (2021) 9:3. 10.3390/vaccines9030275
105.
FedeleFAriaMEspositoVMicilloMCecereGSpanoMet al. COVID-19 vaccine hesitancy: a survey in a population highly compliant to common vaccinations. Hum Vaccin Immunother. (2021) 17:3348–54. 10.1080/21645515.2021.1928460
106.
Gagneux-BrunonADetocMBruelSTardyBRozaireOFrappePet al. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey. J Hosp Infect. (2021) 108:168–73. 10.1016/j.jhin.2020.11.020
107.
GallèFSabellaEARomaPDe GiglioOCaggianoGTafuriSet al. Knowledge and acceptance of COVID-19 vaccination among undergraduate students from Central and Southern Italy. Vaccines. (2021) 9:6. 10.3390/vaccines9060638
108.
GraffignaGPalamenghiLBocciaSBarelloS. Relationship between citizens' health engagement and intention to take the COVID-19 vaccine in Italy: a mediation analysis. Vaccines. (2020) 8:4. 10.3390/vaccines8040576
109.
GrochowskaMRatajczakAZdunekGAdamiecAWaszkiewiczPFeleszkoWet al. comparison of the level of acceptance and hesitancy towards the influenza vaccine and the forthcoming COVID-19 vaccine in the medical community. Vaccines. (2021) 9:5. 10.3390/vaccines9050475
110.
GuaraldiFMontaltiMDi ValerioZMannucciENreuBMonamiMet al. Rate and predictors of hesitancy toward SARS-CoV-2 vaccine among type 2 diabetic patients: results from an Italian survey. Vaccines. (2021) 9:5. 10.3390/vaccines9050460
111.
HammerCCCristeaVDubTSiveläJ. High but slightly declining COVID-19 vaccine acceptance and reasons for vaccine acceptance, Finland April to December 2020. Epidemiol Infect. (2021) 149:e123. 10.1017/S0950268821001114
112.
HolevaVParlapaniENikopoulouVANouskasIDiakogiannisI. COVID-19 vaccine hesitancy in a sample of Greek adults. Psychol Health Med. (2021) 27:113–9. 10.1080/13548506.2021.1948579
113.
IkiişikHAkif SezerolMTaşçiYMaralI. COVID-19 vaccine hesitancy: a community-based research in Turkey. Int J Clin Pract. (2021) 75:e14336. 10.1111/ijcp.14336
114.
JanssenCMaillardABodeletCClaudelALGaillatJDeloryTet al. Hesitancy towards COVID-19 vaccination among healthcare workers: a multi-centric survey in France. Vaccines. (2021) 9:6. 10.3390/vaccines9060547
115.
KaplanAKSahinMKParildarHAdadan GuvencI. The willingness to accept the COVID-19 vaccine and affecting factors among healthcare professionals: a cross-sectional study in Turkey. Int J Clin Pract. (2021) 75:e14226. 10.1111/ijcp.14226
116.
KonopińskaJObuchowskaILisowskiŁDubNKozeraMRekasM. Intention to get COVID-19 vaccinations among ophthalmology residents in Poland: a cross-sectional survey. Vaccines. (2021) 9:4. 10.3390/vaccines9040371
117.
KourlabaGKourkouniEMaistreliSTsopelaCGMolochaNMTriantafyllouCet al. Willingness of Greek general population to get a COVID-19 vaccine. Glob Health Res Policy (2021) 6:3. 10.1186/s41256-021-00188-1
118.
La VecchiaCNegriEAlicandroGScarpinoV. Attitudes towards influenza vaccine and a potential COVID-19 vaccine in Italy and differences across occupational groups, September 2020. Med Lav. (2020) 111:445–8. 10.23749/mdl.v111i6.10813
119.
LeddaCCostantinoCCucciaMMaltezouHCRapisardaV. Attitudes of healthcare personnel towards vaccinations before and during the COVID-19 pandemic. Int J Environ Res Public Health. (2021) 18:5. 10.3390/ijerph18052703
120.
MaleszaMWittmannE. Acceptance and intake of COVID-19 vaccines among older Germans. J Clin Med. (2021) 10:7. 10.3390/jcm10071388
121.
MurphyJVallièresFBentallRPShevlinMMcBrideOHartmanTKet al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. (2021) 12:29. 10.1038/s41467-020-20226-9
122.
NohlAAfflerbachCLurzCBruneBOhmannTWeichertVet al. Acceptance of COVID-19 vaccination among front-line health care workers: a nationwide survey of emergency medical services personnel from Germany. Vaccines. (2021) 9:5. 10.3390/vaccines9050424
123.
PalamenghiLBarelloSBocciaSGraffignaG. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. Eur J Epidemiol. (2020) 35:785–8. 10.1007/s10654-020-00675-8
124.
PatakaAKotoulasSStefanidouEGrigoriouITzinasATsiouprouIet al. Acceptability of healthcare professionals to get vaccinated against COVID-19 two weeks before initiation of national vaccination. Medicina. (2021) 57:6. 10.3390/medicina57060611
125.
PratiG. Intention to receive a vaccine against SARS-CoV-2 in Italy and its association with trust, worry and beliefs about the origin of the virus. Health Educ Res. (2020) 35:505–11. 10.1093/her/cyaa043
126.
PuteikisKMameniškieneR. Factors associated with COVID-19 vaccine hesitancy among people with epilepsy in Lithuania. Int J Environ Res Public Health. (2021) 18:8. 10.3390/ijerph18084374
127.
RenoCMaiettiEFantiniMPSavoiaEManzoliLMontaltiMet al. Enhancing COVID-19 vaccines acceptance: results from a survey on vaccine hesitancy in Northern Italy. Vaccines. (2021) 9:4. 10.3390/vaccines9040378
128.
Rodríguez-BlancoNMontero-NavarroSBotella-RicoJMFelipe-GómezAJSánchez-MásJTuellsJ. Willingness to be vaccinated against COVID-19 in Spain before the start of vaccination: a cross-sectional study. Int J Environ Res Public Health. (2021) 18:10. 10.3390/ijerph18105272
129.
SchwarzingerMWatsonVArwidsonPAllaFLuchiniS. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health. (2021) 6:e210–21. 10.1016/S2468-2667(21)00012-8
130.
SerrazinaFSobral PinhoACabralGSalavisaMCorreiaAS. Willingness to be vaccinated against COVID-19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients. Mult Scler Relat Disord. (2021) 51:102880. 10.1016/j.msard.2021.102880
131.
ShermanSMSmithLESimJAmlôtRCuttsMDaschHet al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Hum Vaccin Immunother. (2021) 17:1612–21. 10.1080/21645515.2020.1846397
132.
SoaresPRochaJVMonizMGamaALairesPAPedroARet al. Factors associated with COVID-19 vaccine hesitancy. Vaccines. (2021) 9:3. 10.3390/vaccines9030300
133.
StuckelbergerSFavreGCeulemansMNordengHGerbierELambeletVet al. SARS-CoV-2 vaccine willingness among pregnant and breastfeeding women during the first pandemic wave: a Cross-sectional study in Switzerland. Viruses. (2021) 13:7. 10.3390/v13071199
134.
TalarekEWarzechaJBanasiukMBanaszkiewiczA. Influenza vaccination coverage and intention to receive hypothetical Ebola and COVID-19 vaccines among medical students. Vaccines. (2021) 9:7. 10.3390/vaccines9070709
135.
TavolacciMPDechelottePLadnerJ. COVID-19 vaccine acceptance, hesitancy, and resistancy among university students in France. Vaccines. (2021) 9:6. 10.3390/vaccines9060654
136.
Trabucco AurilioMMenniniFSGazzilloSMassiniLBolcatoMFeolaAet al. Intention to Be Vaccinated for COVID-19 among Italian nurses during the Pandemic. Vaccines. (2021) 9:5. 10.3390/vaccines9050500
137.
TranVDPakTVGribkovaEIGalkinaGALoskutovaEEDorofeevaVVet al. Determinants of COVID-19 vaccine acceptance in a high infection-rate country: a cross-sectional study in Russia. Pharm Pract. (2021) 19:2276. 10.18549/PharmPract.2021.1.2276
138.
ValléeAFournEMajerholcCTouchePZucmanD. COVID-19 vaccine hesitancy among French people living with HIV. Vaccines. (2021) 9:4. 10.3390/vaccines9040302
139.
WilliamsLFlowersPMcLeodJYoungDRollinsLThe catalyst project T. social patterning and stability of intention to accept a COVID-19 vaccine in Scotland: will those most at risk accept a vaccine?Vaccines. (2021) 9:1. 10.3390/vaccines9010017
140.
YilmazMSahinMK. Parents' willingness and attitudes concerning the COVID-19 vaccine: a cross-sectional study. Int J Clin Pract. (2021) 75:e14364. 10.1111/ijcp.14364
141.
YurttasBPoyrazBCSutNOzdedeAOztasMUgurluSet al. Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. Rheumatol Int. (2021) 41:1105–14. 10.1007/s00296-021-04841-3
142.
Akiful HaqueMMRahmanMLHossianMMatinKFNabiMHSahaSet al. Acceptance of COVID-19 vaccine and its determinants: evidence from a large sample study in Bangladesh. Heliyon. (2021) 7:e07376. 10.1016/j.heliyon.2021.e07376
143.
HarapanHWagnerALYufikaAWinardiWAnwarSGanAKet al. Acceptance of a COVID-19 vaccine in Southeast Asia: a cross-sectional study in Indonesia. Front Public Health. (2020) 8:381. 10.3389/fpubh.2020.00381
144.
JacobJStephenSIssacAKrishnanNVadakkethil RadhakrishnanRVijayVRet al. Determinants of willingness for COVID-19 vaccine: Implications for enhancing the proportion of vaccination among Indians. Cureus. (2021) 13:e15271. 10.7759/cureus.15271
145.
KumariARanjanPChopraSKaurDKaurTUpadhyayADet al. Knowledge, barriers and facilitators regarding COVID-19 vaccine and vaccination programme among the general population: a cross-sectional survey from one thousand two hundred and forty-nine participants. Diabetes Metab Syndr. (2021) 15:987–92. 10.1016/j.dsx.2021.04.015
146.
PandaDSGiriRKNagarajappaAKBashaS. Covid-19 vaccine, acceptance, and concern of safety from public perspective in the state of Odisha, India. Hum Vaccin Immunother. (2021) 17:3333–7. 10.1080/21645515.2021.1924017
147.
WirawanGBSMahardaniPCahyaniMRKLaksmiNJanuragaPP. Conspiracy beliefs and trust as determinants of COVID-19 vaccine acceptance in Bali, Indonesia: Cross-sectional study. Pers Individ Dif. (2021) 180:110995. 10.1016/j.paid.2021.110995
148.
WongLPAliasHWongPFLeeHYAbuBakarS. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum Vaccin Immunother. (2020) 16:2204–14. 10.1080/21645515.2020.1790279
149.
AlleySJStantonRBrowneMToQGKhalesiSWilliamsSLet al. As the pandemic progresses, how does willingness to vaccinate against COVID-19 evolve?Int J Environ Res Public Health. (2021) 18:2. 10.3390/ijerph18020797
150.
AttwellKLakeJSneddonJGerransPBlythCLeeJ. Converting the maybes: Crucial for a successful COVID-19 vaccination strategy. PLoS ONE. (2021) 16:e0245907. 10.1371/journal.pone.0245907
151.
BaiWCaiHLiuSLiuHQiHChenXet al. Attitudes toward COVID-19 vaccines in Chinese college students. Int J Biol Sci. (2021) 17:1469–75. 10.7150/ijbs.58835
152.
ChenMLiYChenJWenZFengFZouHet al. An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccination. Hum Vaccin Immunother. (2021) 17:2279–88. 10.1080/21645515.2020.1853449
153.
EdwardsBBiddleNGrayMSollisK. COVID-19 vaccine hesitancy and resistance: correlates in a nationally representative longitudinal survey of the Australian population. PLoS ONE. (2021) 16:e0248892. 10.1371/journal.pone.0248892
154.
GanLChenYHuPWuDZhuYTanJet al. Willingness to receive SARS-CoV-2 vaccination and associated factors among Chinese adults: a cross sectional survey. Int J Environ Res Public Health. (2021) 18:4. 10.3390/ijerph18041993
155.
HanKFrancisMRZhangRWangQXiaALuLet al. Confidence, acceptance and willingness to pay for the COVID-19 vaccine among migrants in Shanghai, China: a cross-sectional study. Vaccines. (2021) 9:5. 10.3390/vaccines9050443
156.
HuynhGNguyenTVNguyenDDLamQMPhamTNNguyenHTN. Knowledge about COVID-19, beliefs and vaccination acceptance against COVID-19 among high-risk people in Ho Chi Minh City, Vietnam. Infect Drug Resist. (2021) 14:1773–80. 10.2147/IDR.S308446
157.
KadoyaYWatanapongvanichSYuktadattaPPutthinunPLarteySTKhanMSR. Willing or hesitant? a socioeconomic study on the potential acceptance of COVID-19 vaccine in Japan. Int J Environ Res Public Health. (2021) 18:9. 10.3390/ijerph18094864
158.
KwokKOLiKKWeiWITangAWongSYSLeeSS. Editor's Choice: Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: a survey. Int J Nurs Stud. (2021) 114:103854. 10.1016/j.ijnurstu.2020.103854
159.
LinYHuZZhaoQAliasHDanaeeMWongLP. Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China. PLoS Negl Trop Dis. (2020) 14:e0008961. 10.1371/journal.pntd.0008961
160.
LiuDLuoLXieFYuZMaZFWangYet al. Factors associated with the willingness and acceptance of SARS-CoV-2 vaccine from adult subjects in China. Hum Vaccin Immunother. (2021) 17:2405–14. 10.1080/21645515.2021.1899732
161.
LukTTZhaoSWuYWongJYWangMPLamTH. Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: a population-based survey. Vaccine. (2021) 39:3602–7. 10.1016/j.vaccine.2021.05.036
162.
MachidaMNakamuraIKojimaTSaitoRNakayaTHanibuchiTet al. Acceptance of a COVID-19 vaccine in Japan during the COVID-19 pandemic. Vaccines. (2021) 9:3. 10.3390/vaccines9030210
163.
QinWWangENiZ. Chinese consumers' willingness to get a COVID-19 vaccine and willingness to pay for it. PLoS ONE. (2021) 16:e0250112. 10.1371/journal.pone.0250112
164.
SealeHHeywoodAELeaskJSheelMDurrheimDNBolsewiczKet al. Examining Australian public perceptions and behaviors towards a future COVID-19 vaccine. BMC Infect Dis. (2021) 21:120. 10.1186/s12879-021-05833-1
165.
SunYChenXCaoMXiangTZhangJWangPet al. Will healthcare workers accept a COVID-19 vaccine when it becomes available? a cross-sectional study in China. Front Public Health. (2021) 9:664905. 10.3389/fpubh.2021.664905
166.
TaoLWangRLiuJ. Comparison of vaccine acceptance between COVID-19 and seasonal influenza among women in China: a national online survey based on health belief model. Front Med. (2021) 8:679520. 10.3389/fmed.2021.679520
167.
ThakerJ. The persistence of vaccine hesitancy: COVID-19 vaccination intention in New Zealand. J Health Commun. (2021) 26:104–11. 10.1080/10810730.2021.1899346
168.
TsaiFJYangHWLinCPLiuJZ. Acceptability of COVID-19 vaccines and protective behavior among adults in Taiwan: associations between risk perception and willingness to vaccinate against COVID-19. Int J Environ Res Public Health. (2021) 18:11. 10.3390/ijerph18115579
169.
WalkerANZhangTPengXQGeJJGuHYouH. Vaccine acceptance and its influencing factors: an online cross-sectional study among international college students studying in China. Vaccines. (2021) 9:6. 10.3390/vaccines9060585
170.
WangCHanBZhaoTLiuHLiuBChenLet al. Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: a national cross-sectional study. Vaccine. (2021) 39:2833–42. 10.1016/j.vaccine.2021.04.020
171.
WangJLuXLaiXLyuYZhangHFenghuangYet al. The changing acceptance of COVID-19 vaccination in different epidemic phases in China: a longitudinal study. Vaccines. (2021) 9:3. 10.3390/vaccines9030191
172.
WangKWongELHoKFCheungAWYauPSDongDet al. Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong, China: repeated cross-sectional surveys. Vaccines. (2021) 9:1. 10.3390/vaccines9010062
173.
WangKWongELYHoKFCheungAWLChanEYYYeohEKet al. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: a cross-sectional survey. Vaccine. (2020) 38:7049–56. 10.1016/j.vaccine.2020.09.021
174.
WongMCSWongELYHuangJCheungAWLLawKChongMKCet al. Acceptance of the COVID-19 vaccine based on the health belief model: a population-based survey in Hong Kong. Vaccine. (2021) 39:1148–56. 10.1016/j.vaccine.2020.12.083
175.
XuBGaoXZhangXHuYYangHZhouYH. Real-world acceptance of COVID-19 vaccines among healthcare workers in perinatal medicine in China. Vaccines. (2021) 9:7. 10.3390/vaccines9070704
176.
YanELaiDWLLeeVWP. Predictors of intention to vaccinate against COVID-19 in the general public in Hong Kong: findings from a population-based, cross-sectional survey. Vaccines. (2021) 9:7. 10.3390/vaccines9070696
177.
YangFLiXSuXXiaoTWangYHuPet al. A study on willingness and influencing factors to receive COVID-19 vaccination among Qingdao residents. Hum Vaccin Immunother. (2021) 17:408–13. 10.1080/21645515.2020.1817712
178.
ZhangKCFangYCaoHChenHHuTChenYQet al. Parental acceptability of COVID-19 vaccination for children under the age of 18 years: cross-sectional online survey. JMIR Pediatr Parent. (2020) 3:e24827. 10.2196/24827
179.
WangJJingRLaiXZhangHLyuYKnollMDet al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines. (2020) 8:3. 10.3390/vaccines8030482
180.
RiadAAbdulqaderHMorgadoMDomnoriSKoščíkMMendesJJet al. Global prevalence and drivers of dental students' COVID-19 vaccine hesitancy. Vaccines. (2021) 9:6. 10.3390/vaccines9060566
181.
SkjefteMNgirbabulMAkejuOEscuderoDHernandez-DiazSWyszynskiDFet al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol. (2021) 36:197–211. 10.1007/s10654-021-00728-6
182.
AkelKBMastersNBShihSFLuYWagnerAL. Modification of a vaccine hesitancy scale for use in adult vaccinations in the United States and China. Hum Vaccin Immunother. (2021) 17:2639–46. 10.1080/21645515.2021.1884476
183.
LiuTHeZHuangJYanNChenQHuangFet al. A Comparison of vaccine hesitancy of COVID-19 vaccination in China and the United States. Vaccines. (2021) 9:6. 10.3390/vaccines9060649
184.
Asadi FaeziNGholizadehPSanogoMOumarouAMohamedMNCissokoYet al. Peoples' attitude toward COVID-19 vaccine, acceptance, and social trust among African and Middle East countries. Health Promot Perspect. (2021) 11:171–8. 10.34172/hpp.2021.21
185.
BonoSAFaria de Moura VillelaESiauCSChenWSPengpidSHasanMTet al. Factors affecting COVID-19 vaccine acceptance: an international survey among low- and middle-income countries. Vaccines. (2021) 9:5. 10.3390/vaccines9050515
186.
WangQYangLJinHLinL. Vaccination against COVID-19: a systematic review and meta-analysis of acceptability and its predictors. Prev Med. (2021) 150:106694. 10.1016/j.ypmed.2021.106694
187.
SallamM. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. (2021) 9:2. 10.3390/vaccines9020160
188.
Al-JayyousiGFSherbashMAMAliLAMEl-HeneidyAAlhussainiNWZElhassanMEAet al. Factors influencing public attitudes towards COVID-19 vaccination: a scoping review informed by the socio-ecological model. Vaccines. (2021) 9:6. 10.3390/vaccines9060548
189.
Al-AmerRManezeDEverettBMontayreJVillarosaARDwekatEet al. COVID-19 vaccination intention in the first year of the pandemic: a systematic review. J Clin Nurs. (2021) 31:62–86. 10.1111/jocn.15951
190.
TroianoGNardiA. Vaccine hesitancy in the era of COVID-19. Public Health. (2021) 194:245–51. 10.1016/j.puhe.2021.02.025
191.
LazarusJVWykaKRauhLRabinKRatzanSGostinLOet al. Hesitant or not? The association of age, gender, and education with potential acceptance of a COVID-19 vaccine: a country-level analysis. J Health Commun. (2020) 25:799–807. 10.1080/10810730.2020.1868630
192.
LiMLuoYWatsonRZhengYRenJTangJet al. Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review. Postgrad Med J. (2021). [Epub ahead of print]. 10.1136/postgradmedj-2021-140195
193.
UllahIKhanKSTahirMJAhmedAHarapanH. Myths and conspiracy theories on vaccines and COVID-19: potential effect on global vaccine refusals. Vacunas. (2021) 22:93–7. 10.1016/j.vacun.2021.01.001
194.
WakeAD. The Willingness to receive COVID-19 vaccine and its associated factors: “Vaccination refusal could prolong the war of this pandemic” - a systematic review. Risk Manag Healthc Policy. (2021) 14:2609–23. 10.2147/RMHP.S311074
195.
BrandstetterSBöhmerMMPawellekMSeelbach-GöbelBMelterMKabeschMet al. Parents' intention to get vaccinated and to have their child vaccinated against COVID-19: cross-sectional analyses using data from the KUNO-Kids health study. Eur J Pediatr. (2021) 180:3405–10. 10.1007/s00431-021-04094-z
196.
KaplanRMMilsteinA. Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci U S A. (2021) 118:10. 10.1073/pnas.2021726118
197.
HarderTKochJVygen-BonnetSKülper-SchiekWPilicARedaSet al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Eurosurveillance. (2021) 26:2100563. 10.2807/1560-7917.ES.2021.26.28.2100563
198.
JinQRazaSYousafMZamanUSiangJ. Can communication strategies combat COVID-19 vaccine hesitancy with trade-off between public service messages and public skepticism? experimental evidence from Pakistan. Vaccines. (2021) 9:1–22. 10.3390/vaccines9070757
199.
GoossenKHessSLunnyCPieperD. Database combinations to retrieve systematic reviews in overviews of reviews: a methodological study. BMC Med Res Methodol. (2020) 20:138. 10.1186/s12874-020-00983-3
Summary
Keywords
COVID-19, vaccine, acceptance, meta-analysis, prevalence
Citation
Norhayati MN, Che Yusof R and Azman YM (2022) Systematic Review and Meta-Analysis of COVID-19 Vaccination Acceptance. Front. Med. 8:783982. doi: 10.3389/fmed.2021.783982
Received
27 September 2021
Accepted
28 December 2021
Published
27 January 2022
Volume
8 - 2021
Edited by
Zisis Kozlakidis, International Agency for Research on Cancer (IARC), France
Reviewed by
Marta Malesza, Jagiellonian University, Poland; Bijaya Kumar Padhi, Post Graduate Institute of Medical Education and Research (PGIMER), India
Updates
Copyright
© 2022 Norhayati, Che Yusof and Azman.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ruhana Che Yusof ruhanacyf@gmail.com
†These authors have contributed equally to this work
This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.